Retatrutide Cost in Minnesota (2026): Pricing, Insurance, and Savings

What Retatrutide Costs at Minnesota Retail Pharmacies

Brand-name retatrutide at a Minnesota retail pharmacy carries a list price set by Eli Lilly. Without insurance or a discount program, the monthly cash-pay cost reflects this manufacturer pricing. Prices at individual pharmacies across the Twin Cities metro, Rochester, Duluth, and outstate Minnesota may vary by $20 to $80 depending on the pharmacy's acquisition cost and dispensing fee.

The actual price you pay depends on three variables: your insurance formulary tier, whether your plan requires step therapy through another GLP-1 first, and whether you qualify for Eli Lilly's savings card. A patient with a preferred commercial formulary placement could see copays between $25 and $75 per month, while an uninsured patient pays the full retail rate. Pharmacy benefit managers (PBMs) like Express Scripts, CVS Caremark, and OptumRx each negotiate different net prices with Lilly, so two Minnesotans with different employers can pay very different amounts for the same drug 1.

Price-comparison tools such as GoodRx and RxSaver aggregate Minnesota pharmacy pricing in real time. Checking these before filling a prescription takes less than two minutes and can reveal spreads of 15% to 30% between pharmacies within the same ZIP code.

How the Eli Lilly Savings Card Works in Minnesota

Eli Lilly offers a manufacturer savings card for commercially insured patients that caps monthly out-of-pocket costs. The card applies at the point of sale when you fill your prescription at any participating Minnesota pharmacy.

Eligibility is straightforward. You must carry commercial insurance (not Medicare Part D, Medicaid, or TRICARE), fill at a U.S. retail pharmacy, and have a valid prescription. Patients meeting these criteria can reduce their copay to as low as $25 per month for up to 24 months, though the exact cap and duration are subject to Lilly's current program terms 2.

The card does not apply to deductible phases of high-deductible health plans in the same way. If your plan uses an accumulator adjustment program, the savings-card value may not count toward your annual deductible or out-of-pocket maximum. Minnesota's Department of Commerce has not yet passed accumulator-adjustment legislation similar to bills in other states, so checking with your plan's benefits team is a necessary step before assuming the card will reduce your total annual spend.

Minnesota Medicaid Coverage for Retatrutide

Minnesota Medicaid (Medical Assistance) covers retatrutide for chronic weight management with prior authorization. This means your prescribing clinician must submit documentation showing you meet specific clinical criteria before the state will approve payment 3.

Prior authorization criteria typically require a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea. Your clinician will also need to document that you have attempted lifestyle modifications (diet and exercise) for a defined period, usually 3 to 6 months, before pharmacotherapy approval.

Minnesota's Medicaid preferred drug list (PDL) determines whether retatrutide sits on a preferred or non-preferred tier. Preferred placement means a simpler PA process. Non-preferred placement means the state may require you to try and fail a preferred alternative first, a policy called step therapy. MinnesotaCare enrollees follow a similar formulary pathway. Processing times for PA requests in Minnesota average 24 to 72 hours when submitted electronically through the state's PA portal 4.

Dr. Robert Kushner, a professor of medicine at Northwestern University, has noted: "Triple-receptor agonists represent the next generation of obesity pharmacotherapy, and payer coverage decisions will shape how quickly patients can access them." This observation applies directly to Minnesota's Medicaid framework, where formulary placement decisions affect tens of thousands of enrollees who meet BMI thresholds for treatment.

Is Compounded Retatrutide Legal in Minnesota?

Yes. Compounded retatrutide is available in Minnesota through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by Section 503A of the Federal Food, Drug, and Cosmetic Act 5.

A 503A pharmacy compounds medications based on individual patient prescriptions. The pharmacy must be licensed by the Minnesota Board of Pharmacy, and the prescribing clinician must have a valid patient-prescriber relationship. Compounded retatrutide is not an FDA-approved finished product. It is a pharmacy-prepared formulation using the active pharmaceutical ingredient (API).

Pricing for compounded retatrutide in Minnesota typically runs lower than brand-name retail pricing, though the exact savings depend on the compounding pharmacy's sourcing costs, the prescribed dose, and whether the pharmacy offers multi-month supply discounts. Patients considering this route should verify three things: that the pharmacy holds a current Minnesota Board of Pharmacy license, that it sources API from an FDA-registered facility, and that the compounding pharmacist performs appropriate potency and sterility testing 6.

One consideration specific to compounded formulations: insurance plans, including Minnesota Medicaid, generally do not cover compounded medications. Compounded retatrutide is almost exclusively a cash-pay option. This makes it a practical choice for uninsured patients or those whose insurance denies coverage for the brand-name product, but it does require paying out of pocket.

Which Insurance Plans Cover Retatrutide in Minnesota?

Coverage varies by payer type. The three categories that matter for Minnesota residents are commercial insurance, Medicaid, and Medicare.

Commercial insurance. Large employers in Minnesota, including those headquartered in the Twin Cities (UnitedHealth Group, Target, 3M, Best Buy), set their own formulary preferences through their PBM contracts. Some plans have added retatrutide to their formularies with step-therapy requirements or prior authorization. Others exclude anti-obesity medications entirely. Your plan's Summary of Benefits and Coverage (SBC) document or a call to your PBM's member services line will confirm your specific coverage status.

Minnesota Medicaid. Covered with prior authorization, as described above 7.

Medicare Part D. Historically, Medicare Part D has not covered anti-obesity medications. Legislative changes through the Treat and Reduce Obesity Act and related proposals have expanded coverage for some weight-management drugs. Medicare beneficiaries in Minnesota should check their Part D plan's formulary directly or contact 1-800-MEDICARE to confirm whether retatrutide is included in their specific plan year 8.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends that "weights and insurance status should not be barriers to evidence-based obesity pharmacotherapy" 9. This position supports ongoing advocacy for broader payer coverage in Minnesota and nationally.

Getting Retatrutide via Telehealth in Minnesota

Minnesota permits telehealth prescribing of retatrutide. A clinician licensed in Minnesota can evaluate you via video visit, establish a patient-prescriber relationship, and write a prescription that you fill at any Minnesota pharmacy or a licensed mail-order pharmacy.

The Minnesota Board of Medical Practice requires that the telehealth encounter include a real-time audio-video interaction for initial prescriptions of controlled substances, but retatrutide is not a scheduled controlled substance. This means asynchronous (store-and-forward) telehealth encounters may also be acceptable for follow-up visits, depending on the clinician's judgment and the platform's protocols 10.

Telehealth platforms that prescribe GLP-1 receptor agonists and multi-receptor agonists typically charge a consultation fee ranging from $50 to $199 per visit. Some platforms bundle the consultation fee with the medication cost, particularly when dispensing from an affiliated 503A compounding pharmacy. Minnesota residents in rural areas, including the Iron Range, western Minnesota, and the Boundary Waters region, may find telehealth particularly useful given the distance to endocrinology or obesity-medicine specialists.

Why Retatrutide Pricing Reflects Its Clinical Profile

Retatrutide is a first-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This mechanism distinguishes it from dual agonists like tirzepatide (GIP/GLP-1) and single agonists like semaglutide (GLP-1 only). The phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine (N=338) demonstrated dose-dependent weight loss of up to 24.2% of body weight at 48 weeks in participants with obesity, compared to 2.1% in the placebo group 11.

That 24.2% figure exceeds the weight-loss efficacy reported in key trials of both semaglutide 2.4 mg (STEP-1, N=1,961 to 14.9% at 68 weeks) and tirzepatide 15 mg (SURMOUNT-1, N=2,539 to 22.5% at 72 weeks) 12. The triple-receptor mechanism also showed improvements in glycemic control, with HbA1c reductions of up to 2.02 percentage points in participants with type 2 diabetes.

These efficacy numbers inform pricing. Lilly's pricing strategy for retatrutide reflects both development costs and the competitive positioning against tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic). For Minnesota patients comparing options, the choice between retatrutide and alternatives involves weighing efficacy differences, insurance formulary placement, and net out-of-pocket cost after savings programs.

Cheapest Ways to Access Retatrutide in Minnesota

Minnesota patients have several cost-reduction strategies worth evaluating in a specific order.

Step 1: Check insurance formulary status. Call your PBM or log into your plan's drug lookup tool. If retatrutide is covered, even at a non-preferred tier, the copay after applying the Eli Lilly savings card may be your lowest-cost option.

Step 2: Apply the manufacturer savings card. If commercially insured, register at Lilly's savings program website and present the card at your pharmacy. Confirm with your plan whether your copay assistance counts toward your deductible.

Step 3: Evaluate compounded retatrutide. If uninsured or if your plan excludes anti-obesity medications, a licensed Minnesota 503A pharmacy may offer compounded retatrutide at a lower monthly cost than cash-pay retail. Request certificates of analysis for potency and sterility before filling.

Step 4: Compare telehealth-bundled pricing. Some telehealth platforms offer all-inclusive monthly pricing that covers the consultation, prescription, and compounded medication shipped to your Minnesota address. Compare total monthly cost against pharmacy-only pricing plus a separate office visit copay.

Step 5: Ask about patient assistance. Eli Lilly operates the Lilly Cares Foundation for patients below certain income thresholds. Eligibility typically requires household income at or below 400% of the federal poverty level and no prescription drug coverage for the medication 13.

Dose Titration and Monthly Cost Implications

Retatrutide uses a dose-titration schedule. You start at a lower dose and increase over several weeks to reach your maintenance dose. This titration affects your monthly cost because the lower starting doses may cost less per injection than the full maintenance dose, particularly in cash-pay and compounded settings.

A typical titration schedule spans 16 to 20 weeks before reaching the target maintenance dose. During titration, your monthly medication cost may be 20% to 40% lower than your eventual steady-state cost. Plan financially for the full maintenance-dose price, not the introductory titration price, when budgeting for long-term treatment 14.

Adherence to the titration schedule also affects clinical outcomes. In the Jastreboff phase 2 trial, participants who reached the highest dose tier (12 mg weekly) achieved the greatest weight loss (24.2%), while those on lower doses saw proportionally less reduction. Your clinician will adjust your dose based on tolerability and response, with common side effects including nausea (reported in 25.6% of participants at the highest dose), diarrhea, and decreased appetite 15.